GENECEPT ASSAY OPEN LABEL TRIAL RESULTS PUBLISHED IN THE PRIMARY CARE COMPANION FOR CNS DISORDERS

Study results show significant improvement in treatment outcomes for psychiatric patients after undergoing pharmacogenetic testing.

King of Prussia, PA – April 20, 2015 – Genomind, a pharmacogenetic testing laboratory specializing in personalized medicine in the field of psychiatry, today announced the publication of a naturalistic study demonstrating significant improvements in clinical outcomes with the use of the Genecept™ Assay. This study, entitled, “A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients with Mood and Anxiety Disorders”, appears in Volume 17, Issue 2 of The Primary Care Companion for CNS Disorders.

The study examined the effectiveness of the Genecept Assay, a genetic test that informs clinicians on treatment response to psychotrophic medications. Baseline surveys from patients and clinicians were collected to identify patient diagnosis and disease severity, current medication regimen, side effect burden, depression and anxiety symptoms, quality of life, and demographics. Symptoms were re-evaluated one and three months after new treatment plans were established based on the results of the Genecept Assay.

Clinician rated data using the Clinician Global Impression Improvement scale (CGI-I) showed that:

- 87% of patients demonstrated a clinically measurable improvement.
- 62% of patients showed a significant clinical improvement (rated much improved or very much improved).

Patients also reported significant improvements in depression and anxiety, medication side effects, and quality of life. These findings are particularly impressive given that more than two-thirds of patients were reported as treatment-resistant (having at least two failed adequate medication trials prior to testing).

The published article can be viewed online here: http://www.psychiatrist.com/PCC/article/Pages/2015/v17n02/14m01717.aspx

The study was conducted in conjunction with researchers at Massachusetts General Hospital and was authored by – Roy H. Perlis, M.D., MSc., Maurizio Fava, M.D., Herbert Harris, M.D. Ph.D., Francis X. Brennan, Ph.D., Kathryn R. Gardner, M.S., Jay Lombard, D.O., and Rachel Scott, Pharm.D.
FOR IMMEDIATE RELEASE

The *Primary Care Companion for CNS Disorders* is an online, peer-reviewed, abstracted publication designed to inform and educate primary care physicians and other health care professionals who treat patients suffering from mental and neurological illnesses.

**About Genomind**
Genomind is a pharmacogenetic testing laboratory specializing in personalized medicine in the field of psychiatry, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at [http://www.genomind.com](http://www.genomind.com).

**About the Genecept™ Assay**
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic markers that best inform patient response to different psychiatric treatments. The Assay is Genomind’s core product and utilizes a proprietary panel of biomarker tests, providing an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, PTSD, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit [http://www.genomind.com/the-science-behind-the-test/](http://www.genomind.com/the-science-behind-the-test/).

---

For more information, contact:

**Kristina Habermann**
Vice President of Marketing and Corporate Communications
Office: 267.989.3425
Mobile: 267.326.2166
khabermann@genomind.com